Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501096 | 0.79 | BDKRB1 (0.45) | BDKRB1MCHR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4816308 | 0.78 | BDKRB1 (0.45) | BDKRB1MCHR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5950942 | 0.78 | SMN1; SMN2 (0.47) | BDKRB1SMN1; SMN2ALDH1A1HTTTDP1 | |
| SCHEMBL5950940 | 0.78 | SMN1; SMN2 (0.47) | BDKRB1SMN1; SMN2ALDH1A1HTTTDP1 | |
| SCHEMBL3593320 | 0.75 | BDKRB1 (0.49) | BDKRB1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3593313 | 0.75 | BDKRB1 (0.49) | BDKRB1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4150192 | 0.72 | BDKRB1 (0.40) | BDKRB1MCHR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4147058 | 0.69 | KMT2A (0.53) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL4133986 | 0.69 | LTA4H (0.44) | MCHR1KMT2AMEN1PRMT5WDR77 | |
| SCHEMBL13574529 | 0.68 | CYP2D6 (0.71) | KMT2ASMN1; SMN2KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | BDKRB1 51/4885MCHR1 3006/4885KMT2A 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.